cyrilzakka/clinical-trials huggingface dataset:
Incidince of Acute Kidney Injury in Children With Community Acquired Pneumonia at Assiut University Children Hospital

Descriptive prospective observational study of Incidince of acute kidney injury in children with community acquired pneumonia at assiut university children hospital

Community acquired pneumonia (CAP) is a prevalent cause of infectious mortality worldwide \[1, 2\]. The number of patients hospitalized with CAP in the United States has been estimated to have reached one million in 2020, with similarly significant increases globally \[3\]. In Egypt, it was estimated that 10% of children deaths below the age of 5 years is likely caused by pneumonia and other acute respiratory infections \[4\] Acute kidney injury (AKI) is an abrupt decrease in glomerular filtration rate that can lead to health consequences for children in both the short and long term \[5\]. In fact, AKI may increase hospitalization length and morbidity and mortality rates for patients in the short term. Meanwhile, it exposes them to an increased risk of chronic kidney disease (CKD) over time. Even mild AKI doubles the risk of CKD during follow-up \[6\] . AKI is a common condition among hospitalized children. Reports indicate that AKI can exacerbate several typical pediatric disorders, such as acute gastroenteritis with an AKI prevalence of around 25% \[7\], type 1 diabetes mellitus onset with a prevalence rate of approximately 45% \[8\], and acute appendicitis at roughly 7% incidence levels\[9\] . Acute kidney injury (AKI) frequently complicates CAP; its incidence ranges from18-34 %in CAP patients\[10-12\]. Chawla et al., previously reported that coexisting pneumonia and AKI led to worse outcomes than either pneumonia or AKI alone\[13\]. Even among non-severe cases diagnosed only as pneumonia, however,Aki was associated with long-term mortality\[11\]. Despite this evidence, the impactof Aki on inhospital outcomes remains unclear for Egyptian populations . Adults suffering from CAP present considerable risks when it comes to developing both acute kidney injury(AKI)\[14-15\]and later chronic kidney disease(CKD)\[16\]; we hypothesize that there might be under-recognition regarding the prevalence of AKIs among children hospitalized due to CAP-especially milder forms. Indeed even milder forms double CKD risks during follow-ups.\[17\]Thus,it becomes crucially important to detect any episodes of Aki in order plan appropriate patient follow-ups.

Eligibility Criteria:
Inclusion Criteria:

- Patients age \<18 years who are diagnosed with x-ray confirmed communityacquired pneumonia(CAP)

Exclusion Criteria:

* We excluded patients with preexistent comorbidities potentially affecting the Severity of pneumonia
A Clinical Study to Assess the Effects of JoyRise Recovery Powder on Mitigating Alcohol Aftereffects.

This study assesses the effectiveness of JoyRise Recovery Powder in reducing alcohol aftereffects, cognitive impairment, and anxiousness among participants aged 35-54 who consume alcohol. Participants will be randomly assigned to either the JoyRise group or a placebo group. The study will measure hangover symptoms, cognitive function, and overall well-being through a series of questionnaires and cognitive tests at baseline, 30 minutes after product consumption, and 4 hours later.


Eligibility Criteria:
Inclusion Criteria:

* Aged 35-54, male or female
* Regular alcohol consumption
* Event planned within one month that involves alcohol consumption
* Willingness to avoid new medications or supplements during the study period
* Must confirm that they will not drive while under the influence of alcohol.

Exclusion Criteria:

* Anyone not in good health.
* Anyone who has any chronic health conditions such as oncological or psychiatric disorders.
* Anyone who has any known serious allergic reactions that require the use of an Epi-Pen.
* Anyone who is pregnant, breastfeeding, or trying to conceive.
* Anyone who cannot/ will not commit to the study protocol.
* Anyone with a history of substance abuse.
* Anyone who has undergone an invasive medical procedure in the six months prior to the study, or has a procedure planned during the study duration.
* Anyone currently using any medications that may affect their response to alcohol or impact hangover symptoms, such as diuretics (water pills) or medication for hypertension.
* History of severe reactions or sensitivity to alcohol.
* Anyone currently taking glutathione.
Prophylactic Antibiotics or Placebo After Hypospadias Repair

The primary purpose of this study is to determine if routine use of prophylactic (preventive) antibiotics after repair of mid-to-distal hypospadias is beneficial.

Participants in this multicenter, double-blind study are randomized to receive trimethoprim-sulfamethoxazole or placebo for 10 days postoperatively. Short- and intermediate-term results will be published after participants complete 6 months and 5 years of follow-up, respectively.

Eligibility Criteria:
Inclusion Criteria:

* mid-to-distal shaft hypospadias
* single-stage hypospadias repair
* length of urethral repair (urethroplasty) less than or equal to 20 mm
* placement of an open-drainage urethral stent at the time of hypospadias repair, with intended duration of stenting for 5-10 days post-operatively

Exclusion Criteria:

* previous hypospadias repair
* prior adverse/allergic reaction or other contraindication to trimethoprim-sulfamethoxazole
* cross-reactivity of an existing medication with trimethoprim-sulfamethoxazole
* any patient condition with elevated risk of infection or adverse outcome from potential infection (e.g., HIV/AIDS, poorly controlled diabetes mellitus or other immunocompromising conditions, congenital heart disease)
* use of antibiotics within seven days prior to hypospadias repair
* foreskin reconstruction at the time of hypospadias repair
* prescription of oral antibiotics other than Study Medication at the time of hypospadias repair
Prostate Biopsies With Target Lesion on MRI

Our objective is to search for clinical, biological and imaging element that would better define the patient population that could benefit from targeted prostate biopsies only (from a cohort of patients who had targeted and non-targeted prostate biopsies).


Eligibility Criteria:
Inclusion criteria:

* Age \> or = at 18 years old
* Prostatic MRI performed at the Montpellier University Hospital
* Realization of targeted prostate biopsies (by fusion of MRI - ultrasound images) and non-targeted biopsies

Exclusion criteria:

* Pre-biopsy MRI performed outside of the Montpellier University Hospital
* MRI with artefacts
* Not performing 12 non-targeted prostate biopsies
Food'to'Go - a Feasibility Study of Post-discharge Meals for Older Patients by the Use of ICT-technology

The research and Innovation program Food'n'Go - Empower aims to develop, test and implement a health technology solution for involvement and increased empowerment of elderly patients and their relatives. The focus is on frequent issues for this group of patients, in the first phase focusing on nutrition and physical activity. Later, the solution will include pain management, management of sleep problems, management of medication, prevention of confusion and coordination of the treatment and care course across sectorial borders. The technology is a tablet-computer, operated by the patient by means of a number of app-like software applications.

The program received in the summer of 2013 one of the Capital Region OPI funding for design and development of the prototype, which is now ready and looking very promising. The next step is a pilot feasibility study testing the usability and acceptability as well as effect during hospitalisation and at home after discharge. The present study - Food'to'Go investigates the intervention in the post-discharge period.

Aim The overall aim of Food'n'Go research- an innovation programme is to develop, test and implement innovative information technology solutions to increase participation and empowerment of older patients and their families, in relation to frequent problems during hospitalisation and the time after.

The aim for the substudy Food'to'Go is to test the feasibility and efficacy of ICT-supported energy- and protein-enforced home-delivered main and in-between meals on older patients, discharged from acute hospitalisation in medical wards. Hereunder:

* Test the technology's relevance, suitability, acceptability and ease of use in relation to the target group
* Test the communication loop between patient and kitchen, and relatives external access to the related website

Welfare and health technologies are often directed at solving problems and meeting the needs of society's most vulnerable groups, often not familiar with computers. We will, in addition to developing the technological solution, examine user-related barriers and preferences for health technology and try to find solutions that can increase older people's possibilities for using technology and achieve empowerment. The program incorporates research and innovation in an iterative process where research provides answers and solutions to the issues arising in relation to the development of the technology (innovation) and the use of it.


Eligibility Criteria:
Inclusion Criteria:

* are 65 years or older
* are admitted to department of internal medicine, O
* have a nutritional risc score of 3 or more
* are discharged to own home
* are able to participate in the project for 12 weeks
* are able to read, write and understand Danish
* live within a radius of 20 km radius from Herlev Hospital

Exclusion Criteria:

* have food allergies or intolerance
* are vegetarians
* are terminally ill
* are included in the RiSK project
* are unable to communicate and co-operate on the use of the tablet computer
Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia

OBJECTIVES:

I. Compare outcome, including graft failure, graft versus host disease, and survival of HLA-identical sibling bone marrow transplants for aplastic anemia using cyclophosphamide with or without antithymocyte globulin as a conditioning regimen.

PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive cyclophosphamide IV over 60 minutes on days -5 to -2 with or without antithymocyte globulin IV over 4 hours.

All patients then receive bone marrow over 60-120 minutes on day 0, 36 hours after the last dose of cyclophosphamide.

Patients are followed at day 100, at 6 months, and at 1 year posttransplant.

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Severe aplastic anemia with the following criteria:

Hypocellular bone marrow with cellularity less than 20%

At least 2 of the following hematologic abnormalities:

* Neutrophil count no greater than 500/mm3
* Platelet count no greater than 20,000/mm3
* Reticulocyte count no greater than 50,000/mm3

HLA-identical sibling donor available

No clonal cytogenetic abnormalities, paroxysmal nocturnal hemoglobinuria, or myelodysplastic syndrome within 3 months of diagnosis of aplastic anemia

No congenital or constitutional aplastic anemia or Fanconi anemia

--Patient Characteristics--

Hepatic: Bilirubin less than 3 times upper limit of normal (ULN)

Renal: Creatinine less than 2 times ULN

Cardiovascular: Normal cardiac function

Other:

* No uncontrolled infection
* No severe concurrent disease
* HIV negative
* Fertile patients must use effective contraception
Dexmedetomidine for Continuous Sedation

The study aims to demonstrate that dexmedetomidine is non-inferior to current best practice sedation with propofol/midazolam and daily sedation stops, in maintaining a target depth of sedation in long-stay intensive care unit (ICU) patients, and that dexmedetomidine, compared with current best practice, reduces the length of ICU stay.


Eligibility Criteria:
Inclusion Criteria:

* Clinical need for sedation and mechanical ventilation
* Receiving full intensive care life support
* Expected stay in ICU of at least 48 hours (h) from time of admission
* Expected requirement for sedation of at least 24h from time of randomisation
* Written informed consent within 36h of ICU admission

Exclusion Criteria:

* Acute severe neurological disorder
* Acute uncompensated circulatory failure at time of randomisation
* Severe bradycardia
* Atrioventricular (AV) conduction block (II-III) unless pacemaker fitted
* Severe hepatic impairment
* Need for muscle relaxation at time of randomisation
* Loss of hearing or vision or any condition interfering significantly with RASS assessment
* Positive pregnancy test or currently lactating
Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)

This study will explore a new approach to treat patients with a medical condition known as systemic lupus erythematosus (SLE) who have been resistant to previous treatments using a new population of cells with capability to restore a normal immune system that will no longer attack the body.

The stated hypothesis is that the SLE condition is caused by an abnormal immune system that can be restored by replenishing the body with a new population of progenitor cells.

The purpose of this study is to evaluate the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell (AlloMSC) transplantation in patients with refractory SLE. Patients with Lupus nephritis and refractory to corticosteroid or cyclophosphamide trials will be enrolled in this trial. The treatment intervention includes a 24 hour pretreatment with cyclophosphamide followed by AlloMSC transplantation. Patients will be admitted to the in-patient service for the 3-5 days for the transplant treatment and will be followed up in the outpatient clinic. All baseline lupus serology, renal function panels will be obtained at pre-treatment admission. Post-transplantation follow-up visits will be at monthly intervals for lupus serology and renal function tests, and every 3 months for analysis of T regulatory population. The transplanted patients will be evaluated by an integrated team of rheumatologists, hematologists and bone marrow transplant specialists every month for the entire duration of the trial (2 years) and every 6-12 months thereafter.

Eligibility Criteria:
Inclusion Criteria:

* All patients fulfilled the American College of Rheumatology (ACR) criteria of SLE, man or woman aged from 15 to 70 years old, SLEDAI≥8;
* Lupus nephritis with 24h urine protein≥1g;
* Refractory disease as determined by failure of the following regimens:

  * Trial of corticosteroids (oral prednisone more than 20 mg/day);
  * Trial of cyclophosphamide 0.4 \~ 0.6 / m2 every two weeks for six months, or other immunosuppressive drugs, such as MMF 2 g / day, for three months;
* Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital;
* Willing to use contraception throughout the study and for 12 mos following treatment.

Exclusion Criteria:

* Abnormal liver function (ALT higher than 3 times the normal value);
* End-stage renal failure;
* Severe heart and pulmonary failure, or other important organs damage;
* Undercontrolled infections
* Pregnant or breast feeding women, male or female who intended to recent pregnancy.
Investigating the Localization of Consciousness Through Patients with Disorders of Consciousness: Anterior Vs. Posterior Cortex Debate

Patients enrolled in the study underwent five assessments using the CRS-R(Coma Recovery Scale-Revised) within 10 days, along with an 18F-FDG-PET scan.

Patients enrolled in the study underwent five assessments using the CRS-R (Coma Recovery Scale-Revised) within 10 days, along with an 18F-FDG-PET (18F-fluorodeoxyglucose-positron emission tomography) scan. The CRS-R evaluations were conducted by professionally trained and highly experienced personnel. During the CRS-R assessments, patients' behavioral responses were recorded in the domains of visual, auditory, motor, oromotor/verbal, communication, and arousal. Based on the optimal CRS-R results obtained within the 10-day period, patients were categorized into MCS (Minimally consciousness state, criteria: consistent command-following, reproducible responses to commands, object recognition, intelligible verbalization, partially accurate communication, object localization, visual pursuit and visual object localization, spontaneous motor responses, object manipulation, and/or localization to noxious stimulation) or UWS (Unresponsive wakefulness syndrome, criteria: preserved wakefulness accompanied by behavioral responses such as localization to sound, auditory startle, visual startle, withdrawal/flexion movements, abnormal posturing, vocalizations/oromotor movements, and reflexive oromotor responses). All patients exhibited stable vital signs. For data analysis, a healthy control group from Belgium was included to compare brain metabolism between patients with disorders of consciousness and healthy individuals.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of disorders of consciousness after 5 CRS-R assessments;
* Age \>18 years;
* Stable vital signs;
* No use of sedatives or neuromuscular blockers within 24 hours prior to enrollment.

Exclusion Criteria:

* Acute-phase patients (injury duration \<28 days);
* Fewer than 5 CRS-R assessments completed within 10 days;
* Patients diagnosed with EMCS (Emerging Minimally Conscious State);
* Patients with unclear diagnoses (cases where experienced evaluators could not reach a consensus diagnosis);
* Patients with persistent seizures.
Bariatric Scalable Internet Treatments

The purpose of the study is to conduct a randomized clinical trial examining the feasibility and effectiveness of two guided self-help behavioral weight loss (gshBWL) treatments delivered via the internet for individuals struggling with weight loss one year following bariatric surgery. The two treatments will consist of 1) gshBWL delivered through the internet only (gshBWL-I) and 2) gshBWL delivered via the internet with additional complementary phone sessions (gshBWL-IP).


Eligibility Criteria:
Inclusion Criteria:

* gastric bypass and sleeve surgery patients from Yale's Bariatric/Gastrointestinal Surgery Program
* surgery 1-2 years prior
* \<60% excess weight loss
* able to read English proficiently enough to read the patient self-help materials and study assessments
* available for the duration of the treatment
* availability of internet and phone to participate in study interventions
* agree to the study procedures

Exclusion Criteria:

* medical status judged by the surgeon as contraindication (rare instances of need for additional surgery or medical instability)
* unable to ambulate
* current medications that influence eating/weight
* current substance dependence or other severe psychiatric disturbance (e.g., suicidality) that requires immediate treatment.
A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma

This randomised, double-blind, placebo-controlled study will evaluate the efficacy and safety of ADC3680 administered once daily as an add-on therapy to inhaled corticosteroids and when co-administered with montelukast in patients with inadequately-controlled asthma. Patients will be randomised to 3 Arms to receive ADC3680, placebo or montelukast.

This is a multi-centre, randomised, placebo-controlled, double blind, parallel group 3-arm study (including montelukast as an active comparator) designed to compare the efficacy and safety of a once daily dose of ADC3680 with placebo in subjects with inadequately-controlled asthma despite receiving a low to moderate dose of an ICS controller therapy, over a 10 week treatment period. At the end of the 10 week treatment period open label montelukast (10 mg) will be added to ADC3680 and placebo arms for a two week extension period to assess whether efficacy of ADC3680 is enhanced by the addition of montelukast compared with montelukast alone. The montelukast arm will continue with 10 mg montelukast alone.

Eligibility Criteria:
Inclusion Criteria:

* Men and women aged 18 years to 50 years (inclusive)
* Diagnosis of asthma (GINA 2011) including a demonstration of reversible airway obstruction
* Pre-bronchodilator FEV1 value ≥ 40% and ≤ 85% of the predicted normal value at baseline
* A score of 1.5 or greater on the Asthma Control Questionnaire at baseline
* Daily use of low to moderate dose of ICS (equivalent to budesonide ≤ 800 µg per day)
* Prescribed a short-acting inhaled bronchodilator as reliever therapy for relief of symptoms
* A peripheral blood eosinophil count ≥ 0.25 x 109/L
* Non-smoker or former smoker who has not smoked in the last six months
* Body mass index (BMI) ≥ 17 and ≤ 35 kg/m2
* Able to comply with the protocol requirements, instructions and restrictions
* Able to provide signed and dated written informed consent

Exclusion Criteria:

* Subjects with severe asthma exacerbation in the 4 weeks prior to consent
* Subjects with respiratory tract infection in the 4 weeks prior to consent
* Subjects with COPD or other relevant lung diseases
* Subjects with clinically significant condition which may compromise subject safety or interfere with study evaluation

Other protocol-defined inclusion/exclusion criteria may apply.
Validity of Measuring Preoperative Fitness Using Seismofit

Physical fitness levels of people waiting for a planned operation are often measured using an exercise test. This is because fitness levels help doctors make a plan to improve each person's chances of a successful recovery after their planned operation. The exercise test requires skilled staff, expensive equipment, a 1 hour appointment, and the patient to exercise heavily during the test.

Ventriject, a small to medium sized enterprise, have designed a device called Seismofit that estimates fitness levels of people from a measurement taken whilst laying down. It measures the vibrations of the chest wall caused by the beating heart and uses this information with additional information, such as height, weight and sex, to estimate fitness. The measurement takes around 5 minutes to perform, does not require heavy exercise, expensive equipment or skilled staff.

The Seismofit device was shown to be accurate in young fairly fit people. It has not been tested in people who undergo an exercise test before an operation, who are less fit on average compared to the people that the device was originally tested on. It is likely that the calculations used to estimate fitness levels with the Seismofit device will need to be adjusted for people waiting for an operation. There are two parts to this study. The first part aims to estimate up to 50 people's fitness with the Seismofit device and use directly measured fitness from their standard exercise test before their operation to adjust the calculations for estimating fitness. The second part of this study aims to have a further 50 people undergo the Seismofit device measurement and compare the estimated fitness level with the results from the standard exercise test before an operation. This is to see if the Seismofit device is valid at estimating fitness in people awaiting surgery.


Eligibility Criteria:
Inclusion:

* Adults awaiting major or complex elective surgery classified by the NICE NG45 guideline
* Referred for and capable of performing a maximum effort CPET as part of standard care within their preoperative assessment
* Able to be fully supine for 5 minutes

Exclusion:

* Pacemaker, implantable defibrillator, or any other implantable electronic device in situ
* Permanent Atrial fibrillation, or other persistent arrhythmia (such as, atrial flutter, bigeminy, trigeminy, frequent premature atrial/ventricular complexes, 2nd degree heart block) documented in the patient's medical history
* Body mass index (BMI) \>35 kg.m-2
* Severe COPD (defined as FEV1 % predicted \<50% \[GOLD report, 2022\])
* Pectus excavatum or other chest wall deformity
* Claudication that limits exercise tolerance
* Unable to perform maximal CPET
* Refusal to give informed consent
* Presence of an absolute contraindication to CPET detailed in the POETTS clinical guideline (Levett et al. 2018).